Dominique Amans

This inventor holds 11 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 8 EPO patents. Top assignees: Glaxosmithkline Intellectual Property (No.2) Limited, Glaxosmithkline LLC, Glaxosmithkline Intellectual Property Development Limited. Active years: 2015-2022.

USPTO Granted Patents = 11 (Patent Applications = 1)

% Patents Active = 54.5

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 7.4

ph-index = 4

Forward Citations = 82(Granted Patents)

Location History:

Stevenage, GB (2015 - 2017)
Middlesex, GB (2018 - 2020)
Singapore, SG (2019 - 2020)
Brentford, GB (2017 - 2022)

Company Filing History:

4 out of 95

Glaxosmithkline Intellectual Property (No.2) Limited

Glaxosmithkline Intellectual Property Development Limited

patents

4. 1 out of 834,411

Other

patents

Years Active: 2015-2022

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11478478 - 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors (2022-10-25),

2. 10815218 - Benzoimidazole derivatives as PAD4 inhibitors (2020-10-27),

3. 10583139 - 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors (2020-03-10),

4. 10407407 - Benzoimidazole derivatives as PAD4 inhibitors (2019-09-10),

5. 10034881 - 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors (2018-07-31),

6. 9670221 - Furopyridines as bromodomain inhibitors (2017-06-06),

7. 9663533 - Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors (2017-05-30),

8. 9637456 - 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors (2017-05-02),

9. 9315487 - Tetrahydroquinoline derivatives useful as bromodomain inhibitors (2016-04-19),

10. 9029395 - Tetrahydroquinoline derivatives useful as bromodomain inhibitors (2015-05-12),

11. 8993554 - Tetrahydroquinoline derivatives useful as bromodomain inhibitors (2015-03-31),

Title: The Innovative Journey of Dominique Amans

Introduction

Dominique Amans, a talented inventor based in Stevenage, GB, has made significant contributions to the field of pharmaceuticals, holding an impressive total of 11 patents. Her work primarily focuses on developing innovative compounds that serve critical roles in therapeutic applications.

Latest Patents

Among her latest patents are two notable inventions. The first is related to "2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors." This invention encompasses novel compounds and pharmaceutical compositions aimed at therapeutic uses. The second patent focuses on "Benzoimidazole derivatives as PAD4 inhibitors." These compounds are designed to serve as PAD4 inhibitors and could prove useful in treating various disorders, including rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis.

Career Highlights

Throughout her career, Dominique has worked with esteemed organizations such as GlaxoSmithKline Intellectual Property Limited and GlaxoSmithKline LLC. Her expertise and innovative mindset have significantly advanced the research and development of new and effective treatments.

Collaborations

Dominique has collaborated with distinguished colleagues, including Christopher Roland Wellaway and Stephen John Atkinson. Such partnerships have propelled her inventions from concept to fruition, fostering a dynamic environment for scientific exploration.

Conclusion

Dominique Amans exemplifies the spirit of innovation within the pharmaceutical industry. Her patent portfolio not only highlights her dedication to advancing healthcare but also underscores the impact of her contributions on the treatment of various complex diseases. As she continues her work, her journey as an inventor will undoubtedly inspire many within the scientific community.